Trichomoniasis Epidemiology Forecast

DelveInsight’s ‘Trichomoniasis – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Trichomoniasis epidemiology in the United States.


Geographies Covered

  • The United States


Study Period: 2017–2030


Trichomoniasis: Understanding

The DelveInsight’s Trichomoniasis epidemiology report gives a thorough understanding of the Trichomoniasis by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Trichomoniasis in the US. Moreover, the report covers the detailed information of the Trichomoniasis epidemiology scenario in the United States.


Epidemiology Perspective by DelveInsight

This section encompassing Trichomoniasis epidemiology provides insights about historical and current patient pool and forecasted trends for the United States. The Trichomoniasis epidemiology data are studied through all possible divisions to better understand the Disease scenario in the United States. This segment covers the epidemiology data in the US from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.


Detailed Epidemiology Segmentation

The Trichomoniasis epidemiology covered in the report provides historical as well as forecasted Trichomoniasis epidemiology scenario in the United States from 2017 to 2030.


The report also provides the epidemiology trends observed in the United States during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Trichomoniasis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The Trichomoniasis report and model provide an overview of the global trends of Trichomoniasis in the United States.
  • The report provides insight into the historical and forecasted patient pool of Trichomoniasis in the United States.
  • The report helps recognize the growth opportunities in the United States concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Trichomoniasis.
  • The report provides the segmentation of the Trichomoniasis epidemiology


Report Highlights

  • 11-year Forecast of Trichomoniasis Epidemiology
  • United States Coverage
  • Diagnosed prevalent cases of Trichomoniasis
  • Gender-specific prevalence of Trichomoniasis
  • Age-specific prevalence of Trichomoniasis
  • Type-specific cases of Trichomoniasis


KOL Views

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the United States concerning the patient population pertaining to Trichomoniasis?
  • What are the key findings pertaining to the Trichomoniasis epidemiology In the United States?
  • What would be the total number of Trichomoniasis patients’ in the United States during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in the United States during the forecast period (2017–2030)?
  • What is the disease risk, burden, and unmet needs of Trichomoniasis?
  • What are the currently available treatments of Trichomoniasis?


Reasons to buy

The Trichomoniasis Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Trichomoniasis market.
  • Quantify patient populations in the global Trichomoniasis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Trichomoniasis therapeutics in each of the markets covered
  • Understand the magnitude of Trichomoniasis population by its epidemiology
  • The Trichomoniasis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Trichomoniasis

3. SWOT Analysis for Trichomoniasis

4. Disease Background and Overview

4.1. Introduction

4.2. Cause

4.3. Symptoms

4.4. Pathogenesis

4.5. Immune response against trichomoniasis

4.6. Risk Factors

4.7. Clinical presentation

4.8. Diagnosis

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Assumptions and Rationale – United States

5.3. The United States

5.3.1. Diagnosed Prevalent Cases of Trichomoniasis in the United States

5.3.2. Gender-specific Cases of Trichomoniasis in the United States

5.3.3. Age-specific Cases of Trichomoniasis in the United States

5.3.4. Type-specific Cases of Trichomoniasis by Symptoms in the United States

6. Treatment

7. Guidelines

7.1. Trichomoniasis: Diagnostic and Treatment Guidelines by CDC

8. Unmet Needs

9. Organizations contributing toward Trichomoniasis

10. Case Reports

10.1. A Missed Diagnosis of Trichomoniasis

10.2. A Resistant Case of Familial Nonsexual Transmission of Trichomonas

10.3. The Tricky Trichomonas: A Tale of Resistance

11. Patient Journey

11.1. Patient Journey: General

12. Marketed Therapies

13. Emerging Therapies

13.1. Secnidazole: Lupin Research Inc

13.1.1. Product Description

13.1.2. Other Development Activities

13.1.3. Clinical Development

13.1.4. Safety and Efficacy

14. Trichomoniasis: Market Analysis

14.1. Key Findings

14.2. Market Outlook: The United States

14.2.1. The United States Market Size

15. Market Drivers

16. Market Barriers

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Trichomoniasis Market, Epidemiology, and Key Events (2017–2030)

Table 2: Diagnostic Clues for Vaginal Infections

Table 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017–2030)

Table 4: Gender-specific Cases of Trichomoniasis in the United States (2017–2030)

Table 5: Age-specific Cases of Trichomoniasis in the United States (2017–2030)

Table 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017–2030)

Table 7: Options for Treating Metronidazole-Resistant Trichomoniasis

Table 8: Organizations contributing to Trichomoniasis in the United States

Table 9: Secnidazole, Clinical Trial Description, 2020

Table 10: United States Market Size of Trichomoniasis in USD Million (2017–2030)

Table 11: The US Market Size of Trichomoniasis by Therapies in USD Million (2017–2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: Overview of Diagnostic Assays for Trichomoniasis

Figure 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017–2030)

Figure 4: Gender-specific Cases of Trichomoniasis in the United States (2017–2030)

Figure 5: Age-specific Cases of Trichomoniasis in the United States (2017–2030)

Figure 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017–2030)

Figure 7: Unmet Needs of Trichomoniasis

Figure 8: Market Size of Trichomoniasis in the United States, USD Million (2017–2030)

Figure 9: The US Market Size of Trichomoniasis by Therapies in USD Million (2017–2030)

Figure 10: Market Drivers of Trichomoniasis

Figure 11: Market Drivers of Trichomoniasis

  • Tags:
  • Trichomoniasis Epidemiology
  • Trichomoniasis
  • Trichomoniasis Pipeline
  • Trichomoniasis Companies
  • Trichomoniasis prevalent populatio...
  • Trichomoniasis incident population
  • Trichomoniasis patients diagnosed
  • Trichomoniasis treatment algorithm...

Forward to Friend

Need A Quote